Caribou Biosciences vs X4 Pharmaceuticals
CRBU and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and XFOR compare
X4 Pharmaceuticals is the larger company, worth 8.0 times as much as Caribou Biosciences ($309M against $38.8M).
X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus 1.6% for Caribou Biosciences).
X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −1085% at Caribou Biosciences.
Caribou Biosciences scores higher on the StockData Score (8 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | XFOR |
|---|---|---|
| Size and price | ||
| Market cap | $38.8M | $309M |
| Share price | $0.362 | $3.12 |
| Change, 1 year | −84.0% | −19.4% |
| Change, 5 years | −98.3% | −97.8% |
| Beta (5Y) | 1.94 | 1.41 |
| Employees | 97 | 45 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.1× (better) | 31.2× |
| P/B | 0.5× (better) | 2.2× |
| FCF yield | −240% | – |
| Fair value | $1.08 | – |
| Margin of safety | 66.4% | – |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 73.7% (better) |
| Revenue growth, 5Y average | −2.0% | 16.7% (better) |
| Profitability | ||
| Gross margin | – | 68.8% |
| Operating margin | −1141% | −812% (better) |
| Net margin | −1085% | −813% (better) |
| FCF margin | −985% | – |
| Return on equity | −93.8% | −80.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9.3× |
| Current ratio | 4.97 | 13.22 (better) |
| Altman Z-score | −9.18 | −2.09 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −69.3% | – |
| Shareholder yield | −69.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 103% |
| Held by insiders | 5.7% | 12.2% |
| Insider net buying, 12 months | −$47.5K (better) | −$451K |
| Short interest, % of float | 14.7% | 9.2% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- XFOR stock overview
- XFOR income statement
- XFOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.